Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Net Margin (2022 - 2026)

bioAffinity Technologies has reported Net Margin over the past 5 years, most recently at 268.63% for Q1 2026.

  • Quarterly Net Margin fell 12510.0% to 268.63% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 280.57% through Mar 2026, down 17002.0% year-over-year, with the annual reading at 241.96% for FY2025, 14541.0% down from the prior year.
  • Net Margin was 268.63% for Q1 2026 at bioAffinity Technologies, down from 196.98% in the prior quarter.
  • Over five years, Net Margin peaked at 81.53% in Q1 2024 and troughed at 427778.96% in Q3 2022.
  • The 5-year median for Net Margin is 294.25% (2025), against an average of 42730.41%.
  • The largest YoY upside for Net Margin was 42701145bps in 2023 against a maximum downside of -207425bps in 2023.
  • A 5-year view of Net Margin shows it stood at 71380.35% in 2022, then surged by 100bps to 107.22% in 2023, then fell by -25bps to 134.4% in 2024, then crashed by -47bps to 196.98% in 2025, then tumbled by -36bps to 268.63% in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Net Margin are 268.63% (Q1 2026), 196.98% (Q4 2025), and 349.3% (Q3 2025).